Dasher Neuroscience Inc.

Dasher Neuroscience is an AI-driven,
clinical-stage company developing safe, effective, and innovative CNS therapies. Its flagship drug YA-101 holds Orphan Drug Designation in the US, EU, and Japan, as
well as Fast Track Designation in the US for multiple system atrophy (MSA). YA-101 is currently in Phase 2 trials across the US, Japan, and Taiwan.

• Clinical Trial Collaboration
• CRO
• Out-Licensing
• In-Licensing
• Collaborative R&D
• Co-Development